Home » Newsletters » BioWorld Science

BioWorld Science

June 10, 2020

View Archived Issues

C12orf49 is new lipid metabolism gene

Simultaneous dual base editing

Dual JAK1/TYK2 inhibitor TLL-018 shows dose-dependent anti-inflammatory activity in arthritis models

Phase I data presented for URAT1 inhibitor D-0120

FDA clears IND application for PTX-35

BeyondSpring presents positive data from PROTECTIVE-2 study of plinabulin plus Neulasta

First patient dosed in phase Ib study of RMC-4630 in combination with AMG-510

First-in-human data for MGD-013 in unresectable or metastatic neoplasms

HX-008 plus irinotecan show promising activity in advanced gastric adenocarcinoma

TV technology wants to be brain delivery's all-terrain vehicle

Loss-of-function mutations in JAM2 gene cause familial brain calcification

Phase I study finds manageable toxicity with LY-2880070 alone and with gemcitabine

Black Belt TX patents arginase inhibitors

Taisho Pharmaceutical discloses new antibacterials

Grey Wolf Therapeutics synthesizes ERAP1 inhibitors

Merck & Co. describes new adenosine A2A and/or A2B receptor antagonists

Opthea reports phase IIa topline data on OPT-302 for refractory DME

Bacainn announces phase I study initiation for ulcerative colitis candidate BT-051

NLRP3 inhibitors presented by Novartis Inflammasome Research

Wharton's jelly-derived mesenchymal stem cells effective in graft-versus-host disease trial

FDA allows phase III protocol for SPI-1005 for Meniere's disease

Fulcrum submits IND for phase III study of losmapimod for COVID-19

Pfizer reports topline data from JADE TEEN trial of abrocitinib in adolescent atopic dermatitis

NFlection initiates phase IIa study of NFX-179 gel for cutaneous NF-1

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...